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TransplantatABSTRACT
Rhodococcus equi is a gram-positive coccobacillus responsible for severe infections in patients
with weakened immune systems. R equi generally causes pnumonia that may evolve into fatal
systemic infection if left untreated. Here, we present a case of a 67-year-old woman affected
by acute intermittent porphyria (AIP) who developed R equi pneumonia 7 months after
kidney transplant. Although clinical features at presentation were nonspecific, lung
computed tomography showed right perihilar consolidation with a mass-like appearance
causing bronchial obstruction. Appropriate antibiotic including intravenousmeropenem and
oral azithromycin thatwas then switched to oral levofloxacin and oral azithromycin alongwith
reduction of immunosuppressive therapy resolved pneumonia without provoking an acute
attack of porphyria. AIP limited the choice of antibiotics for the treatment ofR equi infection
because some potentially porphyrinogenic antibacterial agents were avoided. Based on this
experience, azithromycin and meropenem can be safely administered for the treatment of R
Equi infection in patients with AIP.Disclosure: The authors declare no conflicts of interest. The
authors declare that they have no competing interest.
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gaetano.md@gmail.comRHODOCOCCUS equi is a gram-positive coccobacillusresponsible for zoonotic infections expressing mainly as
bronchopneumonia, abscess, lymphadenitis, or ulcerative
enterocolitis [1]. The bacterium has a worldwide distribu-
tion; its presence has been documented mainly in horse
manure, soil, and water [2]. The first human case of R equi
infection presenting with cavitary pneumonia was reported
in 1967 in a young man with autoimmune hepatitis on ste-
roid therapy [3]. R equi may cause potentially life-threating
infections that affect predominantly immunocompromised
patients affected by HIV infection and hematologic diseases
or organ transplant recipients [4]. R equi infection generally
presents with insidious onset and typically manifests with
pneumonia. To date, there is no standard treatment for this
disease, and in transplant recipients treatment is based
largely on the use of a long-term combination of 2 or more
antibiotics.
We report a case of pneumonia due to R equi infection in
a kidney transplant recipient also affected by acute inter-
mittent porphyria (AIP). We review issues regarding path-
ogenesis, clinical presentation, diagnosis, and treatment oflished by Elsevier Inc.
enue, New York, NY 10169
ion Proceedings, XX, 1e6 (2018)R equi infection and discuss difficulties faced in choosing the
best antimicrobial therapy in a patient prone to develop a
potentially fatal acute attack if exposed to unsafe (por-
phyrinogenic) drugs.
CASE DESCRIPTION
A 67-year-old woman affected by AIP presented with nonproduc-
tive cough lasting more than 6 weeks (Fig 1). The patient had un-
dergone kidney transplant from a deceased donor 7 months prior
after having been on chronic hemodialysis treatment for 40 months.
The origin of kidney failure was undetermined; the long history of
hypertension associated with the likely nephrotoxic effect of
porphyrin precursors was considered the main cause of her chronic
kidney disease.0041-1345/18
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Fig 1. Timeline representing the principal investigations, antimicrobial and immunosuppressive therapy, and trend in creatinine during
days 0e285 after kidney transplant. Abbreviations: AIP, acute intermittent porphyria; ALA, aminolevulinic acid dehydratase deficiency
porphyria; BID, twice a day; HCP, hereditary coproporphyria; MMF, mycophenolate mofetil; QD, once a day; VP, variegate porphyria.
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the age of 23 and 24. Urinary excretion of porphobilinogen steadily
elevated over time, but she did not experience other acute attacks of
AIP. She was a nonsmoker with an unremarkable history of pul-
monary disease. Additionally, she reported allergy to penicillin and
ciprofloxacin. At the time of kidney transplant, induction with
basiliximab and maintenance therapy with tacrolimus (TAC),
mycophenolate mofetil (MMF), and steroid were well tolerated
without triggering any acute exacerbations of AIP. Delayed graft
function, paroxysmal atrial fibrillation, and development of new
onset diabetes mellitus complicated the immediate postoperative
period after transplant.
Given the high risk of sulfonamides to provoke an acute attack of
AIP, pentamidine isethionate was used for Pneumocystis jirovecii
pneumonia prophylaxis; pre-emptive therapy was used to prevent
post-transplant cytomegalovirus infection.
At presentation, the patient had no signs of respiratory distress
or chest pain, denied recent episodes of hemoptysis, and was apy-
retic. Fine crackles were clearly audible at the base of the right lung
on physical examination. Laboratory data included a total leuko-
cyte count of 8.05  109/L with a differential of 81.2%: neutrophils,
10.4%; lymphocytes, 9.8%; and monocytes, 7.7%; hemoglobin
was 11.5 g/dL. C-reactive protein level was slightly increased
(3.3 mg/dL; N < 0.7). The patient showed a stable renal allograft
function with an estimated glomerular filtration rate [5] of
29 mL/min. Serum transaminase, bilirubin, electrolyte, and lactate
dehydrogenase values were normal. Immunosuppressive regimen
included TAC (target total trough level [TTL], 7e10 ng/mL),
methylprednisolone (6 mg once daily), and MMF (500 mg twice
daily). Chest radiograph revealed a right lower lobe consolidation,
consistent with community-acquired pneumonia. Given the stable
clinical conditions with a normal hemodynamic profile, the patient
was treated in the outpatient setting. A course of oral antibiotic
with moxifloxacin (400 mg per day) was planned for 10 days, and
MMF was stopped to favor the resolution of the presumptive
bacterial pneumonia. On day 14, after the adequate course ofantibiotic therapy, a second chest radiography was performed
because of the persistence of a nonproductive cough. The presence
of the roundish lung lesion without signs of resolution prompted
the performance of high-resolution computed tomography (CT) of
the lung. The CT imaging revealed a grossly right perihilar mass
measuring 8.5  4 cm that encircled and completely occluded the
lumen of the right lower lobe bronchus and confirmed the smaller
rounded opacity in the right lower lobe previously detected by chest
radiography. Bronchoscopy revealed a broad-based, lobulated
lesion arising from the right main stem bronchus and completely
occluding the lumen of middle and lower lobe bronchus. Cytologic
examination of cells from bronchoalveolar lavage (BAL) showed a
moderate numbers of inflammatory cells, mostly macrophages;
malignant cells were not found. The histologic analysis of the
bronchial biopsy specimen showed a pattern of chronic granulo-
matous disease, accompanied by inflammatory cells of acute phase
(ie, neutrophils). The histiocytes in granuloma showed a granular
eosinophilic cytoplasm (von Hansemann cells) containing several
bacteria displaying coccoid morphology with Gram stain. Addi-
tionally, well-demarked intracytoplasmic inclusion, known as
Michaelis-Gutmann bodies were detected and stained positively
with the Periodic acideSchiffediastase and Grocott stains. These
findings were consistent with a diagnosis of pulmonary malako-
plakia, a condition frequently associated with R equi infection. The
diagnosis was eventually confirmed by the culture results of BAL,
where gram-positive coccobacillus grew on sheep blood and choc-
olate agar plates. Mycobacterial, yeast, and fungal cultures had
negative results in BAL fluid. Blood cultures yielded negative
results. On the basis of these histologic findings, the patient was
admitted for treatment of the infection. Given the occlusion of a
bronchus and the proximity of the lesion to the blood vessels of the
pulmonary hilum, the patient was evaluated by a thoracic surgeon
who suggested aconservative management because of the absence
of recognizable signs of respiratory distress and bleeding. On day
53, the patient started antimicrobial therapy that included intra-
venous meropenem (1 g twice daily) and oral azithromycin (250 mg
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daily dose of 1.5 mg (target TTL, 6e7 mg/dL) in order to favor the
resolution of the infection. The antibiotic therapy was well toler-
ated and yielded a gradual improvement of cough. After 15 days of
treatment, antibiotic therapy was switched to oral levofloxacin (750
mg once daily) and oral azithromycin (250 mg once daily). Several
days later, the patient was discharged while receiving the afore-
mentioned antibiotic regimen that was planned until the resolution
of disease. Serial chest CT scans, performed at 3 and 5 months
from presentation, showed a progressive reduction in size of the
perihilar lesion and a complete resolution of the consolidated area
present in the right lower lobe. After a total duration of slightly
more than 5 months of antibiotic therapy, when the size of perihilar
lesion still measured 4  13 mm, the patient self-discontinued
therapy for poor adherence. Given the high risk of relapse, the
patient was warned to communicate every sign and symptom sug-
gesting lung involvement. Fourteen months after the premature
discontinuation of the antibiotic therapy, the patient remained
asymptomatic, without developing any respiratory diseases or evi-
dence of recurrence on chest radiography. She preserved a stable
graft function with a creatinine of 1.9 mg/dL (estimated glomerular
filtration rate, 25 mL/min [5]) and continued an immunosuppres-
sive regimen based on TAC (target TTL, 6e7.5 mg/dL) and
methylprednisolone (4 mg once daily).DISCUSSION
This case illustrates the complex management of R equi
pneumonia in a kidney transplant recipient affected by AIP.
The main difficulties rely primarily on nonspecific clinical
presentation, lack of a standard antimicrobial treatment,
and presence of a severe underlying inherited disorder that
significantly limited the antibiotic choice. R equi is a
gram-positive, obligate aerobic, nonmotile, and nonspore-
forming organism responsible for rare but severe infec-
tious disease in human beings. The major determinant
factors of its pathogenesis are the capability to be a facul-
tative intracellular microorganism, compromise host cell
functions [6], and induce cell death [7]. The predominant
route of transmission is thought to be the inhalation of
infected aerosol and dust particles from the manure of
herbivore animals [4]. Person-to-person transmission is
infrequent; it was documented in 1998 when Arlotti et al [8]
described an anecdotic case of transmission of the infection
from a patient with R equi pneumonia to 2 HIV-infected
patients sharing the same hospital room. However, there
are cases, as in our patient, in which it is impossible to
determine the source of exposure. Intriguingly, this event is
reported to be more frequent among immunocompetent
patients than immunosuppressed patients.
R equi is the cause of severe and often devastating dis-
ease, and if left untreated it can evolve into fatal systemic
infection. R equi infection has been described commonly
among subjects with an altered immune system response,
such as HIV-positive patients and transplant recipients.
Identification of the bacterium from the site of infection
is the first step for successful management of the disease. To
date, there are several different techniques to achieve the
diagnosis. The conventional culture-based method providesinformation on phenotypic characteristics of culture (ie,
growth pattern and colony morphology), whereas
biochemical tests allow microbial identification by means of
ChristieeAtkinseMunch-Petersen reaction [9] and API
Coryne system (BioMerieux, Marcy-l’Étoile, France) [10].
However, identification of R equi from microbiological
cultures is time-consuming as the bacterium has a long
period of incubation that may require up to 7 days for
identification [11]. On the other hand, polymerase chain
reactionebased assay may be the most accurate and fastest
diagnostic test for R equi identification [12]. The major
drawback, which limits its use, is its scarce availability
outside university hospital and research centers [13]. His-
tologic examination is a useful tool to support the diagnosis
of R equi when malakoplakia is identified on the biopsy
specimen. Malakoplakia is the typical histopathologic
finding seen prevalently in patients with R equi infection,
especially during pulmonary involvement. This lesion is a
rare acquired granulomatous disease, characterized by a
dense infiltrate of foamy histiocytes containing concentric
scattered basophilic inclusion, named Michaelis-Gutmann
bodies, which likely represents the remnants of an
impaired clearance of bacteria ingested by inflammatory
cells [14]. Although malakoplakia is strongly associated with
R equi infection in immunocompromised subjects (espe-
cially in HIV-infected patients), it is a nonspecific lesion
that has been also reported to occur in cases of Mycobac-
terium tuberculosis, Pasteurella multocida, and Escherichia
coli infection [1]. From a practical point of view, the iden-
tification of malakoplakia together with gram-positive coc-
cobacilli should raise a high index of suspicion for R equi.
Hence, as in our case, the collaboration with a skilled
pathologist may be a critical prerequisite to identify the
lesion and establish a presumptive diagnosis of R equi
infection, especially in a center like ours that is not equip-
ped with polymerase chain reaction assay for detecting
R equi.
The most common presentation is necrotizing pneu-
monia, which may be complicated by abscess, empyema,
pleural effusion, and spontaneous pneumothorax. Blood-
stream invasion and peripheral organ dissemination are rare
events and often secondary to lung involvement. Clinical
manifestations of R equi pneumonia are often subacute and
nonspecific. Symptoms of pulmonary involvement were
cough (70%), chest pain (30%), sputum production (20%),
and dyspnea (20%) [15]. Radiologic findings of subjects
diagnosed as having pneumonia are heterogeneous; dense
infiltrates with upper-lobe cavitary lesion [16,17] often
resemble pulmonary tuberculosis [18]. Occlusion of a
bronchus is a rare manifestation of R equi pneumonia, and
only a few cases have been reported in literature to date
[19e21]. In our case, the findings of lobar consolidation,
lymphadenopathy, and bronchial obstruction associated
with no clear signs of incipient infection disease were highly
suggestive of lung cancer.
Antimicrobial therapy is the mainstay of treatment for
R equi infection. Treatment is usually based on multiple
Table 1. Antimicrobials Recommended for Treatment of
Rhodococcus equi Infection in Patient Affected by Acute Form of
Porphyria
Preferred Drug Alternative Drug
Vancomycin (NP) Amoxicillin-clavulanic acid (NP)
Tobramycin (NP) Cefotaxime (PNP)
Gentamicin (NP) Cefoxitin (PNP)
Ampicillin (NP) Ceftriaxone (PNP)
Azithromycin (PNP) Linezolid (PNP)
Ciprofloxacin (PNP)
Levofloxacin (PNP)
Imipenem and cilastatin (PNP)
Meropenem (PNP)
Drugs to Avoid
Rifampicin (P)
Erythromycin (P)
Sulfamethoxazole/
trimethoprim (P)
Clindamycin (PRP)
Clarithromycin (PSP)
Minocycline (NC)
Cefazolin (NC)
Kanamycin (NC)
Amoxicillin/sulbactam (NC)
The drugs are classified into 5 categories regarding their potential ability to
precipitate symptoms: NC, not yet classified; NP, not porphyrinogenic; P, por-
phyrinogenic; PNP, probably not porphyrinogenic; PRP, probably porphyrino-
genic; PSP, possibly porphyrinogenic.
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ceptibilities are not standardized, and the choice of anti-
biotic is still essentially based on single-center experience.
The bacterium is typically susceptible to erythromycin,
rifampicin, ciprofloxacin, vancomycin, aminoglycosides,
imipenem, and meropenem; it is usually resistant to
penicillin and cephalosporin but extremely susceptible to
amoxicillin/clavulanate and ampicillin/sulbactam. The
sensitivity to tetracycline and sulfamethoxazole/trimetho-
prim is variable [22] and it seems to change between the
United States and Europe [23]. The best treatment option is
considered the inclusion at least of 1 antibiotic with
intracellular penetration, such as erythromycin and/or
rifampicin, in order to easily reach the microorganism
within the host cells.
Treatment duration depends on the site, degree of tissue
involvement, and underlying immunocompetence of the
host; for instance, immunosuppressed patients with locali-
zation in the central nervous system and cavitary disease of
the lung usually need a prolonged course of antibiotics.
Transplant recipients need a long course of antibiotic
therapy that include 2 to 6 week induction with an active
intravenous antibiotic such as vancomycin, carbapenem, or
aminoglycoside in combination with active oral drugs until a
clear clinical improvement is established. After that, main-
tenance therapy based on 2 oral drugs continues until all
culture results are negative and the symptoms and radio-
logic abnormalities have resolved. Commonly, pulmonary
infection required at least 6 months of therapy [4]. Surgical
intervention may be requested in cases of extensive or
abscessual lesions [24,25]. The need for tapering or
discontinuing immunosuppressive therapy in transplant re-
cipients during R equi is controversial [24,26]. This decision
should be made in organ transplant recipients with a severe
infectious disease and should be balanced against the ever-
present risk of acute rejection.
Regarding the best treatment of R equi infection in kidney
transplant recipients affected by porphyria, data are lacking
because there are only a few case reports of renal trans-
plantation in patients affected by porphyria [27e30].
Porphyrias are a group of rare diseases, caused mainly by
inherited enzyme activity defects of the biosynthetic heme
pathway [31]. AIP is an autosomal dominant disorder
caused by a defect in hydroxymethylbilane synthase, a heme
biosynthetic enzyme. AIP attacks are characterized by
severe abdominal pain, often accompanied by nausea,
vomiting, tachycardia, and hypertension. The acute attacks
may be complicated by neurologic manifestations (ie, neu-
ropathy, confusion, coma) leading to potentially fatal con-
sequences [32,33]. The identified precipitating factors are
hormonal fluctuations, fasting, smoking, infections, and
exposure to porphyrogenic drugs such as antibiotics. These
conditions increase the concentration of 5-aminolevulinic
acid and porphobilinogen in the liver that are thought to be
neurotoxic [31]. Given this background, pharmacologic
options for an infectious disease that require combination
treatment may be limited in patients with porphyria. Beingaware of the risks of some antibiotics to provoke an acute
attack of porphyria, we selected them cautiously from a
complete list of drugs available on the internet (for Euro-
pean Union countries) [34]. Among antimicrobials
preferred for treating R equi (Table 1), we avoided rifam-
picin, erythromycin, and sulfamethoxazole/trimethoprim
because they are considered porphyrogenic; we avoided
clindamycin and clarithromycin because they are likely to be
porphyrogenic. Minocycline, cefazolin, kanamycin, and
amoxicillin/sulbactam were also excluded because their risk
of triggering an acute attack is unknown. Among drugs with
a safer profile, we first used meropenem and then levo-
floxacin in association with azithromycin, an antibiotic with
intracellular penetrance. The patient was treated with
antibiotic therapy for a total duration of 5 months along
with the withdrawal of MMF. This therapeutic strategy
allowed the successful resolution of pneumonia without
provoking acute attacks of porphyria or interactions with
immunosuppressive drugs. Notwithstanding the reduction of
immunosuppressive therapy, the patient did not develop an
episode of graft rejection. Interestingly, antimicrobial ther-
apy was discontinued prematurely when the disease was
present radiologically, although in gradual resolution. After
15 months of follow-up, the patient had no signs of lung or
systemic relapse. The delayed radiographic resolution of
lung pneumonia, despite the clinical improvement, may
open new questions about the usefulness of imaging in
assessing resolution of pneumonia and guiding antimicro-
bial treatment duration. As with other forms of bacterial
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lags behind clinical improvement [35].
CONCLUSION
We describe the challenging management of a unique case
of R equi infection in a kidney transplant recipient affected
by AIP. The careful selection of combination antibiotic
therapy and reduction of immunosuppression allowed the
successful treatment of pneumonia without triggering an
acute attack of porphyria or an episode of acute rejection.
We believe that use of levofloxacin, azithromycin, and
meropenem can be safely administered for the treatment of
R equi infection in patients with AIP. Further studies are
requested to provide guidelines for the optimal treatment
regimen of R equi infection.
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